Modified Compounds for Fetal Hemoglobin Induction in Hemoglobinopathies
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hemoglobinopathies, such as sickle cell disease and beta-thalassemia, are limited by variable clinical responses, myelotoxicity, and the risk of carcinogenesis, necessitating the development of more effective therapies that can reactivate fetal hemoglobin expression in adult hematopoietic cells.
Innovation Solution
Development of compounds of formulas (I), (II), and (III), along with their pharmaceutically acceptable salts, tautomers, and stereoisomers, which are administered to subjects to treat or prevent hemoglobinopathies, potentially enhancing fetal hemoglobin expression and improving clinical outcomes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If hydroxyurea is used to induce fetal hemoglobin expression, then fetal hemoglobin levels increase, but myelotoxicity and carcinogenesis risk increase
Solution Approach 1:
The patent modifies the chemical structure of hydroxyurea by introducing specific functional groups and molecular moieties to change the pharmacological parameters of the compound. This allows achieving fetal hemoglobin induction with reduced myelotoxicity and carcinogenesis risk, as the modified structure alters the compound's interaction with biological targets while maintaining therapeutic efficacy.
Solution Approach 2:
The invention creates composite molecular structures by combining hydroxyurea core with additional functional groups and molecular fragments. These composite compounds integrate the beneficial fetal hemoglobin-inducing property of hydroxyurea with modified pharmacological characteristics that reduce harmful effects such as myelotoxicity and carcinogenesis.
2Reliability
If adult hemoglobin expression is abnormal, then hemoglobinopathy occurs, but treatment options are limited
Solution Approach 1:
The patent develops a series of compounds that can treat multiple types of hemoglobinopathies (sickle cell disease, beta-thalassemia, alpha-thalassemia) through a unified molecular mechanism. The compounds universally induce fetal hemoglobin expression across different patient populations and disease subtypes, providing versatile treatment options with consistent therapeutic effectiveness.
Solution Approach 2:
The invention systematically modifies molecular parameters of the compounds to optimize their ability to reactivate fetal hemoglobin expression in adult hematopoietic cells. By adjusting structural parameters such as functional groups, molecular weight, and pharmacokinetic properties, the compounds achieve reliable treatment outcomes across diverse hemoglobinopathy presentations.
Data Source
AI summary
Disclosed herein are compounds and methods for the prevention and/or treatment of hemoglobinopathies. Also provided herein are such compounds for use in such methods. Also disclosed herein are pharmaceutical compositions comprising such compounds for use in such methods of preventing or treating hemoglobinopathies.